CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, today announced interim safety data from an open-label Phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary ocular melanoma. The findings were presented by Carol Shields, M.D., Director of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology of Thomas Jefferson University in Philadelphia, during a late-breaking session at the American Academy of Ophthalmology (AAO) 2017 Annual Meeting in New Orleans. The first and second patients in this study were dosed earlier this year by Dr. Shields at Wills Eye Hospital in Philadelphia. The subsequent patients were dosed at centers in Boston, Detroit, Houston and Denver.
AU-011, an investigational, first-in-class targeted therapy, is in development for the treatment of primary ocular melanoma, a rare and life-threatening disease. The Phase 1b/2 open-label, ascending single and repeat dose trial of AU-011, will evaluate the safety (primary objective) and preliminary efficacy (secondary objective) in up to 24 adult patients who have a clinical diagnosis of ocular melanoma.
Interim data presented today at AAO show that the drug candidate was generally well-tolerated, with no serious adverse events reported, in the first six patients at three to six months post-treatment of AU-011. The most commonly reported adverse events consisted of anterior and posterior intraocular inflammation, which was managed with administration of topical and/or oral steroid treatment. All patients maintained visual acuity. The preliminary efficacy measurement of tumor thickness on B-scan ultrasound at three months post-treatment shows that all patients had stable disease at three months, and only one patient experienced tumor progression at five months.
“These preliminary findings are an encouraging step forward in our effort to evaluate the potential of AU-011 for the treatment of ocular melanoma,” said Dr. Shields. “Today there are no treatment options available for patients that can effectively target tumor cells while still preserving vision. We are excited to build on these initial results as this important research progresses.”
“Aura’s goal is to give physicians first-in-class tools that can transform the treatment of ocular melanoma and other cancers when the disease is diagnosed early,” said Cadmus Rich, M.D., Chief Medical Officer of Aura. “These are promising early data, and our team is pleased to continue our Phase 1b/2 study with Dr. Shields and our other collaborators at leading ophthalmology centers of excellence across the country.”
About ocular melanoma
Ocular melanoma, also known as uveal
or choroidal melanoma, develops in the uvea, or uveal tract, of the eye,
and is a rare and aggressive eye cancer. No targeted therapies are
available at present, and current radiotherapy treatments can be
associated with severe visual loss and other long-term sequelae such as
dry eye, glaucoma, cataracts and radiation retinopathy. The most common
current treatment is plaque radiotherapy, which involves surgical
placement of a radiation device against the exterior of the eye over the
tumor. This technique can control the melanoma but can also lead to
radiation-related cataract, retinopathy and loss of vision. The
alternative is enucleation, or removal of the eye. Ocular melanoma
metastasizes to the liver in about 40 percent of cases in the long-term
(source: OMF),
and only 10 to15 percent of patients whose melanoma has metastasized
survive beyond five years after diagnosis (source: ACS).
About light-activated AU-011
AU-011 is a first-in-class
targeted therapy in development for the primary treatment of ocular
melanoma. The therapy consists of viral nanoparticle conjugates that
bind selectively to unique receptors on cancer cells in the eye and is
derived from technology originally pioneered by Dr. John Schiller of the
Center for Cancer Research at the National Cancer Institute (NCI),
recipient of the 2017 Lasker-DeBakey Award. Upon activation with an
ophthalmic laser, the drug rapidly and specifically destroys the
membranes of tumor cells while sparing key eye structures, which may
allow for the potential of preserving patients’ vision and reducing
other long term complications of treatment. AU-011 for ocular melanoma
has been granted orphan drug and fast track designations by the U.S.
Food and Drug Administration and is currently in clinical development.
About Aura Biosciences
Aura Biosciences is developing a new
class of therapies to target and destroy cancer cells selectively. Its
lead program, AU-011 in ocular melanoma, is being developed under a
CRADA with the National Cancer Institute (NCI), part of the National
Institutes of Health. For more information, visit www.aurabiosciences.com.
